Sun Pharma receives approval to manufacture and market generic semaglutide in South Africa

Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its subsidiaries and/or associate companies) announced that it has received approval from the South African Health Products Regulatory Authority (SAHPRA) to manufacture and market a generic version of semaglutide injection in South Africa for the treatment of adults with inadequately controlled type 2 diabetes mellitus as an adjunct to diet and exercise.

Sun Pharma plans to launch the product in the market in the coming days. It will be available as a pre-filled, multi-dose injectable pen in two strengths (2 mg/1.5 mL and 4 mg/3 mL) that allow flexible, once-weekly dosing.

"South Africa is the second market after India where Sun Pharma has received approval for generic semaglutide. This reflects our ability to develop complex generic medicines that meet the stringent quality standards across different markets. We remain committed to improving access to generics and making evidence-based treatment options available to patients and healthcare professionals," said Aalok Shanghvi, Chief Operating Officer, Sun Pharma.

South Africa faces a growing burden of type 2 diabetes, driven in part by rapid urbanization and changing lifestyles. This rising prevalence places significant pressure on patients and healthcare services. Improving access to effective therapies is therefore an important component of addressing this national health challenge.

Shares of Sun Pharmaceutical Industries Limited was last trading in BSE at Rs. 1940.15 as compared to the previous close of Rs. 1924.05. The total number of shares traded during the day was 343638 in over 7692 trades.

The stock hit an intraday high of Rs. 1950.00 and intraday low of 1901.90. The net turnover during the day was Rs. 666901736.00.

Source : Equity Bulls

Keywords

SunPharmaceuticalIndustries INE044A01036 Approval SouthAfrica GenericSemaglutide